Licensing · MENA · Announced 14 Jul 2026
Galenicum → Dar Al Dawa
Licensing deal between Galenicum (Spain) and Dar Al Dawa (Jordan), announced 14 Jul 2026. Value: Undisclosed.
Parties: Galenicum (Spain) → Dar AlDawa (Jordan)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- MENA (specific countries not disclosed)
- Therapeutic area
- Cardiovascular
- Asset
- Select diabetes + cardiovascular products
- Announced
- 14 Jul 2026
Our analysis
Galenicum isn't a commodity generics vendor — it's a B2B product owner . It develops and holds its own dossiers and finished products in Spain, then licenses and supplies them to a local partner in each market rather than building its own salesforce or registrations.
So this deal is Galenicum doing what its model is built for: handing a chronic-care portfolio to a regional partner that already has the footprint to carry it.
The full analysis is free to read with a work email on this page.
Source: Dar Al Dawa